PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA - Z. Zhuang; Y. Tian; L. Shi; D. Zou; R. Feng; W.-W. Tian; H. Yu; F. Dong; A. Liao; Y. Ma; Q. Liu; S. Liu; et al. (HemaSphere, 2022)